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Abstract
Insulin signalling pathways were investigated in a 33 year-old woman with immunologic insulin
resistance. Her past medical history was remarkable for intermittent use of insulin and allergic
reactions to several drugs, and measure of plasma anti-insulin antibodies level corroborated the
clinical suspicion of immune mediated insulin resistance (8074 nU/ml - RIA - Ref value: <60).
Treatment with several immunosuppressive regimens was tried, however the results were
disappointing. Possible subcellular mechanisms of insulin resistance were investigated by
performing analysis of insulin receptor and post receptor signaling in skeletal muscle biopsy. The
expression of insulin receptor (IR), insulin receptor substrate 1 (IRS-1) and glucose transporter 4
(GLUT-4) was evaluated in total extract from muscle tissue by Western blotting. Basal IR, IRS-1
and GLUT-4 expression was detected, however receptor autophosphorylation was not observed.
A study of translocation of GLUT-4 to plasma membrane showed that tissue presented low levels
of membrane-associated GLUT-4. When in vitro stimulation was undertaken, tissue was capable to
be responsive to insulin. Our results suggest that even though IR expression was normally
occurring, IR β-subunit tyrosine kinase activity in muscle was down-regulated leading to alterations
in insulin post receptor signaling. Consistent with normal insulin receptor and post receptor
signaling, our results were compatible with decreased insulin binding to IR probably due to
neutralization by anti-insulin antibodies. In conclusion, this patient has immunologic insulin
resistance and treatment should be based on immunosuppressive drugs as tolerated.
Introduction
Immunologic insulin resistance is a disorder recognized
in the clinical practice for many years [1,2]. Its pathogen-
esis is related to the presence of plasma anti-insulin anti-
bodies, and patients at greatest risk are those who ever
used non-human insulin and those who had a history of
intermitent use of this drug [3]. Treatment interruption
and re-introduction of insulin works as a booster, a very
well-known effect in the immunization practice that
induces the rising of antibodies against the presented anti-
gen. Other patients at risk for the development of anti-
insulin antibodies are those with an allergic history or
with auto-immune diseases [4].
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After excluding the possibility of resistance to the subcuta-
neous route of administration by using the parenteral
route [5] and making a trial of a synthetic insulin ana-
logue [6], treatment is based upon immunosuppression.
Many regimens have already been described as resulting
in good clinical and laboratorial results but there are no
consensus in the literature as to which is the best one [3-
5,7].
We hereby present a case of immunologic insulin resist-
ance that has not responded to many therapeutic immu-
nosuppressive interventions resulting in great anxiety for
assistant physicians and leading us to investigate the pos-
sibility of a subcellular mechanism of disease.
Case Report
A 33 year-old woman with diabetes for 25 years was
treated with NPH insulin (0.77 U/kg/day) when she first
came to our attention. She had a positive history of allergy
to penicillin and no other morbidities. During her adoles-
cence, she had been switched to oral hypoglycemiants for
approximately 4 years, which made her diabetes difficult
to classify.
During follow-up we were able to gradually decrease her
insulin dose until she was successfully switched back to
oral agents. For 11 months she was on a regimen of glybu-
ride (10 mg bid), metformin (850 mg tid) and acarbose
(50 mg tid), before being admitted with hyperosmolar
non-ketotic coma.
After a prolonged hospital stay she was discharged home
using NPH insulin. Over the following months, worsen-
ing glycemic control indicated progressive insulin dose
increments (from 0.6 to 5.7 U/Kg/day). When 2.7 U/Kg/
day was reached, we discarded all causes of secondary dia-
betes and plasma anti-insulin antibodies were determined
(8074 nU/ml - RIA - Ref value: <60). We concluded she
developed immunologic insulin resistance.
Several immunosuppressive regimens were tried such as
glucocorticoids [7], cyclophosphamide [5], immunoglob-
ulin [8] and plasmapheresis [5,7] but the results were dis-
appointing (average glycemia before: 468 mg/dl, insulin
dosage: 490 U/d; average glycemia after: 450 mg/dl, insu-
lin dosage: 450 U/d) and life-threatening infectious com-
plications indicated immunosuppressant interruption
every time.
Subcutaneous resistance to insulin was ruled out by intra-
venous administration during the inpatient period [5].
Thereafter the patient was switched to Lispro [6] adminis-
tered by continuous subcutaneous infusion.
Since we had no success with the various immunosup-
pressive regimens we decided to perform a skeletal muscle
biopsy to investigate possible subcellular mechanisms of
insulin resistance. The patient gave informed consent for
the procedure and it was accepted by the local ethics com-
mittee. Solear muscle was biopsied under topical anesthe-
sia one hour after the patient administered a
subcutaneous insulin bolus followed by a meal. Skeletal
muscle membranes were isolated as described by Ozanne
et al [9]. Expression of insulin receptor (IR), insulin recep-
tor substrate 1 (IRS-1) and glucose transporter 4 (GLUT-
4) was evaluated in total extract from muscle tissue by
Western blotting as previously described by De Freitas et
al [10]. Figure 1A shows basal IR, IRS-1 and GLUT-4
expression. However, when IR tyrosine phosphorylation
(pIR) was analyzed, receptor autophosphorylation was
not observed (Figure 1B) despite the expressive IR expres-
sion. Translocation of GLUT-4 to plasma membrane was
A- IR, IRS-1 and GLUT-4 expression in total extract from  skeletal muscle; B- IR protein content and IR tyrosine phos- phorylation (pIR); C- Membrane-associated GLUT-4 content Figure 1
A- IR, IRS-1 and GLUT-4 expression in total extract 
from skeletal muscle; B- IR protein content and IR 
tyrosine phosphorylation (pIR); C- Membrane-associ-
ated GLUT-4 content. Cellular proteins (30 μg total) 
were subjected to 10% SDS-PAGE, transferred to PVDF fil-
ters and blocked with Tween-TBS containing 1% BSA. Pri-
mary antibodies used in Western analysis were anti-insulin 
receptor β-subunit (IR); anti-IRS-1; anti-GLUT-4 and anti-
phosphotyrosine. PVDF filters were next incubated with 
appropriate secondary antibody conjugated to biotin fol-
lowed by 1-h incubation with horseradish peroxidase-conju-
gated streptavidin. Immunoreactive proteins were visualized 
by DAB staining.
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also investigated in skeletal muscle. Western blotting pro-
tein analysis with anti-GLUT-4 antibody indicated that tis-
sue presented low levels of membrane-associated GLUT-4
(Figure 1C). These findings suggest that even though IR
expression was normally occuring, IR β-subunit tyrosine
kinase activity in muscle was down-regulated leading to
alterations in insulin post receptor signaling. According to
this, IR (pIR) and IRS-1 (pIRS-1) phosphotyrosine con-
tents and GLUT-4 translocation were analyzed by immu-
noblotting before and after in vitro stimulation with
insulin. We found that IR and IRS-1 tyrosine phosphoryla-
tion was highly stimulated by insulin (Figures 2A and 2B)
and GLUT-4 translocation was significantly increased
(Figure 2C). Consistent with normal insulin receptor and
post receptor signaling, our results were compatible with
decreased insulin binding to IR probably due to neutrali-
zation by anti-insulin antibodies. Tissue was showed to be
normally responsive to insulin and the failure in its action
was probably due to the presence of plasma anti-insulin
antibodies.
Once insulin dose still needed to be increased, patient was
started on a combination of micophenolate mophetil (1 g
bid) and prednisone (40 mg/d) in an outpatient basis.
After one year, insulin dose was reduced from 5.8 to 3.48
U/Kg/d and glycemic control, even if not optimum, has
shown some improvement (average glycemia: 390 to <
200 md/dL). It is important to note that patient did not
experience fasting hypoglycemia since severe insulin
resistance developed.
We conclude that this patient has immunologic insulin
resistance of difficult management. The best immunosup-
pressive regimen for her, in terms of improvement in gly-
cemic control, was the combination of prednisone and
micophenolate mophetil, however the results are slow as
a result of the type of response to these drugs. The muscu-
lar biopsy helped to rule out a subcellular mechanism of
insulin resistance that would be more difficult to treat.
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